Abstract
Recent insight into the underlying molecular and cellular mechanisms of fragile X syndrome (FXS) has led to the proposal and
development of new pharmaceutical treatment strategies, and the initiation of clinical trials aimed at correcting core symptoms
of the developmental disorder. Consequently, there is an urgent and critical need for outcome measures that are valid for
quantifying specific symptoms of FXS and that are consistent across time. We used eye tracking to evaluate test–retest reliability
of gaze and pupillometry measures in individuals with FXS and we demonstrate that these measures are viable options for assessing
treatment-specific outcomes related to a core behavioral feature of the disorder.
development of new pharmaceutical treatment strategies, and the initiation of clinical trials aimed at correcting core symptoms
of the developmental disorder. Consequently, there is an urgent and critical need for outcome measures that are valid for
quantifying specific symptoms of FXS and that are consistent across time. We used eye tracking to evaluate test–retest reliability
of gaze and pupillometry measures in individuals with FXS and we demonstrate that these measures are viable options for assessing
treatment-specific outcomes related to a core behavioral feature of the disorder.
- Content Type Journal Article
- Pages 1-8
- DOI 10.1007/s10803-011-1176-2
- Authors
- Faraz Farzin, Department of Psychology, Stanford University, 450 Serra Mall, Stanford, CA 94305, USA
- Felicia Scaggs, College of Medicine, Rush University Medical Center, Chicago, IL USA
- Crystal Hervey, Department of Pediatrics, Rush University Medical Center, Chicago, IL USA
- Elizabeth Berry-Kravis, Department of Pediatrics, Rush University Medical Center, Chicago, IL USA
- David Hessl, Medical Investigation of Neurodevelopmental Disorders (M.I.N.D.) Institute, University of California, Davis, Medical Center, Sacramento, CA USA
- Journal Journal of Autism and Developmental Disorders
- Online ISSN 1573-3432
- Print ISSN 0162-3257